NYSE · Biotechnology · USD
Biohaven Ltd. (BHVN) Stock Analysis
Biohaven Ltd. (BHVN) is a Biotechnology stock listed on NYSE and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
BHVN Key Statistics
As of Sep 4, 2026Trading
- Open
- $15.52
- Previous Close
- $15.86
- Day's Range
- 15.21–15.81
- 52-Week Range
- 7.48–18.57
- Volume
- 1.90M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 3.17
Valuation
- Market Cap
- $2.37B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.50
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$738.82M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 151.04M
- 1-Year Return
- −2.36%
Dividend and dates
- Earnings Date
- November 9, 2026estimated
- Avg Volume
- 3.02M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
BHVN Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +38.97% |
| 2025 | −69.77% |
| 2024 | −12.73% |
| 2023 | +208.36% |
| 2022 (partial year) | +94.51% |
As of September 4, 2026.
BHVN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$738.82M | — |
| 2024 | $0.00 | −$846.42M | — |
| 2023 | $0.00 | −$408.17M | — |
| 2022 | $0.00 | −$570.28M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$745.38M | −$738.82M | — |
| 2024 | $0.00 | — | −$885.11M | −$846.42M | — |
| 2023 | $0.00 | — | −$436.05M | −$408.17M | — |
| 2022 | $0.00 | — | −$567.93M | −$570.28M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
BHVN Valuation vs Biotechnology Median
Median of 656 stocks| Metric | BHVN | Biotechnology median | vs median |
|---|---|---|---|
| Profit margin | 0.00% | 0.00% | 0.0 pts above |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
YahooWhy Biohaven Stock Was Rocking the Market This Week
YahooSK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
YahooBiohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
SeekingAlphaBHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
YahooBiohaven: Sale Of Opakalim Rights To SK Biopharmaceuticals Makes Sense On Many Levels
SeekingAlpha
All 17 articles ↓Show fewer ↑
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout
YahooWhy Is Biohaven Stock Soaring Wednesday?
BenzingaBiohaven shares climb 7% after signing major SK Biopharmaceuticals licensing deal
YahooBiohaven trades cash for ‘upside’ with $795M epilepsy drug deal
YahooBiohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
YahooBiohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront
BenzingaBiohaven And Yale Win $4M Judgment Against Avilar And RA Capital Over Willful Misappropriation Of Yale Trade Secret
BenzingaMorgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $19
BenzingaRBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
BenzingaBiohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate
BenzingaBiohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B